Study for AML after it returns or resists treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that is relapsed (came back) or refractory (didn’t respond), or you have a myeloid-related mixed/biphenotypic AML, including some outside-the-bone-marrow cases
- You are age 18 or older, and you either have relapsed/refractory AML or are newly diagnosed and not able to receive intensive chemotherapy
- Your leukemia must have an IDH1 or IDH2 gene mutation (a specific genetic change)
- Your overall health must allow study treatment (ECOG performance status is 2 or less, if you have a 2–3 score you may still qualify only under the “not eligible for intensive chemo” rules)
- You must meet blood, liver, and kidney lab limits (kidney and liver numbers must be within allowed ranges unless changes are clearly caused by leukemia or specific exceptions apply)
- You must not have certain exclusions like acute promyelocytic leukemia (FAB M3), active severe infections, uncontrolled serious medical/mental health problems, or HIV/hepatitis B or C
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
This Phase 2 trial tests a combination of venetoclax, cladribine, low-dose cytarabine, and azacitidine in people with untreated acute myeloid leukemia (AML). It may help shrink the leukemia and improve blood counts by trying a stronger, multi-drug approach.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This trial tests a combination of three targeted drugs for people with a specific type of AML that has an IDH1 mutation. The goal is to see if the combination helps control the leukemia and if continuing with just ivosidenib can keep it in remission.
This Phase 2 trial tests a combination treatment to try to get rid of remaining cancer cells in young adults whose acute myeloid leukemia (AML) is in remission but still detectable at low levels. It may help patients eliminate “minimal residual disease” (small traces of leukemia cells) and reduce relapse risk.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.